Cita APA

Juliá, E. P., Amante, A., Pampena, M. B., Mordoh, J., & Levy, E. M. (2018). Avelumab, an IgG1 anti-PD-L1 immune checkpoint inhibitor, triggers NK cell-mediated cytotoxicity and cytokine production against Triple Negative Breast Cancer cells. Web

Citación estilo Chicago

Juliá, Estefanía Paula, Analía Amante, María Betina Pampena, Jose Mordoh, and Estrella Mariel Levy. Avelumab, an IgG1 Anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-mediated Cytotoxicity and Cytokine Production against Triple Negative Breast Cancer Cells. 2018.

Cita MLA

Juliá, Estefanía Paula, et al. Avelumab, an IgG1 Anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-mediated Cytotoxicity and Cytokine Production against Triple Negative Breast Cancer Cells. 2018.